XSHG
603008
Market cap588mUSD
Oct 09, Last price
11.08CNY
1D
3.55%
1Q
36.45%
Jan 2017
-39.45%
IPO
53.46%
Name
Xilinmen Furniture Co Ltd
Chart & performance
P/E
16.90
P/S
0.46
EPS
0.66
Div yield, %
7.48%
Shrs. gr., 5y
-1.06%
Rev. gr., 5y
9.42%
Revenues
8.82b
+1.02%
Net income
241m
-25.11%
CFO
841m
+6.91%
Dividend
Nov 26, 20250.28 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Operating in China, Sleemon Healthy Sleep Technology Co., Ltd. specializes in the design, manufacturing, and distribution of bedroom furnishings. Its comprehensive product line includes mattresses, beds, sofas, storage units, and other complementary furniture pieces for bedrooms and guest accommodations. The company markets these items through various brand names, such as Fashman, Erna, Burano, Ximian, and Keshang. Founded in 1993 as Xilinmen Furniture Co., Ltd., the firm is headquartered in Shaoxing, China.
Key people
Ayu Chen
Executive Chairman of the Board · since 2025
Yicheng Chen
President, Vice Chairman of the Board · since 2022
Dongyun Zhang
Chief Financial Officer · since 2023
Yongzhou Jiang
Vice President, General Manager - Administrative Management Center · since 2021
Mingxia Qian
Vice President, Staff Elected Director, General Manager - Operation and Management Center · since 2022
Guang Wu
Vice President · since 2021
Zhenghu Zhang
Vice President · since 2024
Shuangquan Zheng
Vice President · since 2022
Xiaohua Zhu
Vice President, Staff Elected Director · since 2021
Jie Shen
Secretary of the Board · since 2021
Pingqi Chen
Director, General Manager - International Business Center · since 2021
Independent Director · since 2024
Guangchang Wang
Independent Director · since 2024
Feng Zhu
Independent Director · since 2022
Headquarters & legal address
浙江省绍兴市越城区灵芝镇二环北路1号
绍兴市, ZJ 100000
CN
绍兴市, ZJ 100000
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||